AP NEWS
ADVERTISEMENT
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from NewMediaWire
Press release content from NewMediaWire. The AP news staff was not involved in its creation.

ATERIAN CLASS ACTION REMINDER

June 4, 2021 GMT

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Aterian To Contact Him Directly To Discuss Their Options

NEW YORK, NY - ( NewMediaWire ) - June 04, 2021 - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aterian, Inc. (“Aterian” or the “Company”) (NASDAQ: ATER) and reminds investors of the July 12, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. 

If you suffered losses exceeding $50,000 investing in Aterian stock or options between December 1, 2020 and May 3, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ATER.

ADVERTISEMENT

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.


As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company’s organic growth is plummeting; (2) the Company’s recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (3) Aterian’s purported artificial intelligence software is a flawed product that lacks customer interest; (4) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.


On May 4, 2021, Culper Research published a scathing report entitled: “Aterian (ATER): Bought from Felons & Fraudsters, Sold to You.” In this report, Culper wrote that: “the Company has ties to convicted criminals and is promoting what we believe is an over-hyped ‘AI’ narrative and a string of garbage acquisitions to mask the failure of its already ill-conceived core business.” 


Culper continued that: “Aterian has been largely unsuccessful in convincing other Amazon sellers to pay for its ‘AIMEE’ AI platform, and at least 5 former employees and a former customer have expressed doubts regarding AIMEE’s legitimacy.”


Culper further wrote: “[w]e believe that there are serious problems with Aterian’s claims to maintain strong organic growth and to drive M&A synergies: to us, neither of these appears to be the case. . . . In our view, this suggests not only that Aterian is unable to growth EBITDA at acquired businesses, but that its core business is also failing to produce.”


ADVERTISEMENT

On this news, the price of Aterian stock fell from its May 3, 2021 close of $20.66 to a May 5, 2021 close of $15.72 per share, a two-day drop of $4.94 per share or approximately 24%.


The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  


Faruqi & Faruqi, LLP also encourages anyone with information regarding Aterian’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.


Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.